DC Field | Value | Language |
dc.contributor.author | Darciuc, Radu | |
dc.contributor.author | Boiciuc, Irina | |
dc.contributor.author | Eraslan, Hakan | |
dc.contributor.author | Diker, Erdem | |
dc.date.accessioned | 2020-09-24T11:58:42Z | |
dc.date.available | 2020-09-24T11:58:42Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | DARCIUC, Radu, BOICIUC, Irina, ERASLAN, Hakan, DIKER, Erdem. First experience with cryoballoon ablation for atrial fibrillation in Republic of Moldova. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 202. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11782 | |
dc.description | Medpark International Hospital, Cardiology and Interventional Cardiology Department,
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova,
TOBB University of Economics and Technology Hospital, Cardiology Department, Ankara,
Turkey, The 8th International Medical Congress for Students and Young Doctors, September 24-26, 2020 | en_US |
dc.description.abstract | Introduction. Pulmonary vein isolation is an established therapy for symptomatic atrial
fibrillation (AF). The second generation cryoballoon is effective in achieving pulmonary vein
isolation. In 2018 we implemented the cryoballoon ablation (CBA) in Republic of Moldova.Aim of the study. To assess the freedom from AF recurrence after CBA.
Materials and methods. A retrospective study was performed in 8 consecutive patients who
underwent CBA using Arctic Front Advance cryoballoon (Medtronic) for paroxysmal or
persistent AF from June 2018 till December 2019 in Medpark International Hospital. We
followed up the patients from June 2018 till March 2020. The information about the clinical
symptoms and ECG data during follow-up was collected to identify the presence of recurrence.
A recurrence after CBA was considered AF episode that lasted at least 30 seconds. Continuous
variables are presented as mean ± SD. Kaplan–Meier analysis was used to determine the
probability of freedom from AF during follow-up.
Results. A total number of 8 patients with a mean age of 60.13 ± 6.88 years with paroxysmal
(n=7; 87.5%) or persistent (n=1; 12.5%) AF were identified. There were 6 males (75%) and 2
females (25%). All patients had a successful pulmonary vein isolation procedure with 100% of
veins isolated. No patient had complication during procedure as phrenic nerve palsy, stroke or
pericardial effusion. After a 3-month blanking period during a mean follow-up of 337 ± 135
days there were 2 (25%) AF recurrences. One patient developed atrial flutter but not AF in the
follow-up period with restoration of sinus rhythm with electrical cardioversion. The average
days before recurrence was 120.5 ± 41.72 (150 and 90). Freedom from AF recurrence was 75%
at 11,2 months follow-up.
Conclusions. The second generation cryoballoon ablation is an effective method of treatment
for atrial fibrillation. Our results are compatible with the success rate that is reported by
majority of the studies. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | ablation | en_US |
dc.subject | atrial fibrillation | en_US |
dc.subject | cryoballoon | en_US |
dc.subject | pulmonary vein isolation | en_US |
dc.title | First experience with cryoballoon ablation for atrial fibrillation in Republic of Moldova | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2020
|